Full Text
Full text is available in PDF
Official Journal of Research Center for Gastroenterology and Liver Diseases
e-ISSN 1735-3408
p-ISSN 1735-143X
Molecular Diagnosis of Entecavir Resistance
Authors
1Clinical Laboratory, Faculty of Medicine, Umuttepe Kampus, University of Kocaeli, sayanmurat@hotmail.com, Kocaeli, Turkey
*Corresponding Author: Clinical Laboratory, Faculty of Medicine, Umuttepe Kampus, University of Kocaeli, sayanmurat@hotmail.com, Kocaeli, Turkey. Tel: +90 262 303 8571. Fax: +90 262 303 8085. Email: sayanmurat@hotmail.com
Published online:Mar 31, 2010
Article type:Review Article
Received:Nov 21, 2009
Accepted:Jan 14, 2010
How to Cite:Sayan M. Molecular Diagnosis of Entecavir Resistance. Hepat Mon. 2010;10(1):. doi:
Abstract
Entecavir (ETV) is a potent nucleoside analogue against hepatitis B virus (HBV). Because of development of ETV resistance requires at least three amino acid substitutions in HBV polymerase (pol) gene, emergence of ETV resistance is rare (~1%) in nucleoside-naive patients after up to 5 years of treatment. However, it has been suggested that lamivudine (LAM) therapy can preselect for HBV variants associated with resistance to ETV treatment. ETV resistance increased to 51% of patients after 5 years of ETV treatment in LAM refractory patients. The diagnosis of ETV resistance in chronic hepatitis B patients, mainly based on four types of molecular assays: direct sequencing, line probe assay, clonal analysis, and restriction fragment length polymorphism (RFLP) analysis. The applications of other assays are currently more specialized, and their use is more limited. The utility of these assays and their performance characteristics are reviewed below. Briefly, the monitoring of drug-resistant variants is important in the elucidation of the prevalence and mechanisms of resistance development and for the more effective management of treatment options.
Highlights
Copyright
© 2010, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
24
Jan
2018
Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey
Ali Asan,
Murat Sayan,
Sila Akhan,
Suda Tekin Koruk,
Bilgehan Aygen,
Fatma Sirmatel
,et al.Asan A, Sayan M, Akhan S, Tekin Koruk S, Aygen B, et al. Molecular Characterization of Drug Resistance in Hepatitis B Viruses Isolated from Patients with Chronical Infection in Turkey. Hepat Mon. 2018;18(1):e12472. doi: https://doi.org/10.5812/hepatmon.12472
1
Oct
2013
Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance
Bo Qin,
Bo Zhang,
Xiaodong Zhang,
Tingting He,
Wenying Xu,
Lijun Fu
,et al.Qin B, Zhang B, Zhang X, He T, Xu W, et al. Substitution Rtq267h of Hepatitis B Virus Increases the Weight of Replication and Lamivudine Resistance. Hepat Mon. 2013;13(10):e12160. doi: https://doi.org/10.5812/hepatmon.12160
1
Oct
2013
The incidence of Drug- Resistant Mutants in Patients With Chronic HBV Infection After Lamivudine Treatment
Sepide Ezzatpanah Fard,
Zohreh Sharifi,
Seyed Masoud Hosseini,
Mahmood Mahmoodian Shooshtari
Ezzatpanah Fard S, Sharifi Z, Hosseini SM, Mahmoodian Shooshtari M. The incidence of Drug- Resistant Mutants in Patients With Chronic HBV Infection After Lamivudine Treatment. Jundishapur J Microbiol. 2013;6(8):e7366. doi: https://doi.org/10.5812/jjm.7366
20
Feb
2023
Effects of Entecavir on Serum Hepatitis B Virus-DNA, Interferon-γ, and Pregenomic RNA in Patients with Chronic Hepatitis B Virus Infection
Xuyang Gong,
Zhitao Chen,
Xiaoxia Zhang,
Yi Zheng,
Heng Zhang
Gong X, Chen Z, Zhang X, Zheng Y, Zhang H. Effects of Entecavir on Serum Hepatitis B Virus-DNA, Interferon-γ, and Pregenomic RNA in Patients with Chronic Hepatitis B Virus Infection. Hepat Mon. 2023;23(1):e132684. doi: https://doi.org/10.5812/hepatmon-132684
23
Jan
2022
Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial
Tae Hyung Kim,
Minkoo Kim,
Hyung Joon Yim,
Sang Jun Suh,
Young Kul Jung,
Yeon Seok Seo
,et al.Kim TH, Kim M, Yim HJ, Suh SJ, Jung YK, et al. Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial. Hepat Mon. 2021;21(11):e121627. doi: https://doi.org/10.5812/hepatmon.121627
Cited by
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 11
Last Update: 3 weeks ago
- Scopus by Title (Ref): 11
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 10 hours ago
- OpenAlex: 0
Last Update: 1 day ago
- OpenCitations: 0
Last Update: 4 days ago
Comments
Number of Comments:0